[Skip to Navigation]
Views 664
Citations 0
Editor's Note
October 13, 2021

Identifying Treatments for Stage C2 Heart Failure

Author Affiliations
  • 1Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois
  • 2Deputy Editor, JAMA Cardiology
  • 3Division of Cardiology, Duke University School of Medicine, Durham, North Carolina
  • 4Associate Editor, JAMA Cardiology
  • 5Ahmanson-UCLA Cardiomyopathy Center, Ronald Reagan UCLA Medical Center, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles
  • 6Section Editor, JAMA Cardiology
JAMA Cardiol. Published online October 13, 2021. doi:10.1001/jamacardio.2021.4024

Classic pathobiologic and contemporary hierarchal classification schemes for heart failure (HF) establish the progressive nature of the clinical syndrome of HF. Failure to disrupt this cascade results in the well-described and still pressing burden of morbidity and mortality. Compelling research now informs effective interventions for HF stages A, B, C, and D.1 Yet these 4 partitions are very broad and may not reflect the different phenotypes of clinical disease to tailor management. The findings from the Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure (GALACTIC-HF) randomized clinical trial were appropriately welcomed as a new treatment opportunity for patients with HF with reduced ejection fraction (HFrEF) and introduced a new drug class, myotrope, to the vernacular of HF therapeutics.2 However, because the overall clinical benefits among the patients enrolled in the GALACTIC-HF clinical trial were quite modest, a major question emerged: which patients may derive clinically relevant benefits?

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words